Akebia Therapeutics, Inc.

akebia.com

akebia.com • 1001-5000 employees • Founded 2002 • NASDAQ: AKBA

1001-5000 employees • Founded 2002 • NASDAQ: AKBA

Biotechnology

Biologics & Biosimilars

Health Care

As featured in

markets.businessinsider.com

RTTNews

Claim pageClaim

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Overview

Fully integrated renal biopharmaceutical company with a late stage product in global Phase 3 clinical development and a commercially available medicine.

News

News markets.businessinsider.com 16 days ago

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to bet...

Report

Press release BioSpace 20 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 1, 2026 Read more

Report

News RTTNews 1 month ago

Akebia Doses First Patient In Phase 2 Trial Of Ebribafusp For Rare Kidney Diseases

Akebia Therapeutics (AKBA) announced the first patient dosed in a Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseases, including IgA nephropathy, lupus nephritis and C3 glomerulopathy.

Report

News markets.businessinsider.com 1 month ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected...

Report

News zonebourse.com 1 month ago

Akebia Therapeutics administre la première dose au premier patient de l'essai de phase 2 'basket' sur l'ebribafusp dans les maladies rénales rares médiées par le complément Read more

Report

Press release The Globe and Mail 4 months ago

Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio

Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades.

Report

Press release The Globe and Mail 4 months ago

Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near

Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades.

Report

News YahooFinance 7 months ago

Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the 10 best penny stocks that could triple your money. On February 26, Akebia Therapeutics Inc. (NASDAQ:AKBA) outlined its 2026 pipeline expansion and shared expectations for Vafseo data catalysts in the $1